SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731.
Caitlin W ElgartenJohn A KairallaJoel C ThompsonTamara P MillerCindy WangSusan ConwayMignon L LohElizabeth A RaetzSumit GuptaRachel E RauAnne AngiolilloKaren R RabinSarah AlexanderPublished in: EJHaem (2023)
Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).
Keyphrases
- coronavirus disease
- sars cov
- acute lymphoblastic leukemia
- respiratory syndrome coronavirus
- young adults
- electronic health record
- clinical trial
- acute myeloid leukemia
- study protocol
- palliative care
- big data
- phase iii
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- bone marrow
- diffuse large b cell lymphoma
- newly diagnosed
- phase ii
- randomized controlled trial
- chronic kidney disease
- prognostic factors
- emergency department
- machine learning
- early onset
- type diabetes
- insulin resistance
- skeletal muscle
- adipose tissue
- weight loss
- drug induced
- open label
- glycemic control